Teva Pharmaceutical Industries Price to Free Cash Flow Ratio 2010-2024 | TEVA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Teva Pharmaceutical Industries average price to free cash flow ratio for 2023 was 11.32, a 12.52% increase from 2022.
Teva Pharmaceutical Industries average price to free cash flow ratio for 2022 was 12.94, a 77.8% decline from 2021.
Teva Pharmaceutical Industries average price to free cash flow ratio for 2021 was 58.3, a 380.63% decline from 2020.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Teva Pharmaceutical Industries average price to free cash flow ratio for 2023 was 11.32, a 12.52% increase from 2022.
Teva Pharmaceutical Industries average price to free cash flow ratio for 2022 was 12.94, a 77.8% decline from 2021.
Teva Pharmaceutical Industries average price to free cash flow ratio for 2021 was 58.3, a 380.63% decline from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Dr Reddy's Laboratories (RDY)	$13.1B
BridgeBio Pharma (BBIO)	$5B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Taysha Gene Therapies (TSHA)	$449M
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M